Participated · Series C · Oct 2025

Founded in 2018, Chicago-based Sibel Health offers the ANNE® platform, a suite of FDA-cleared wearable sensors integrated with mobile software, cloud analytics, and AI-driven algorithms to capture continuous, real-world vital-sign data. The system is already paired with Samsung mobile devices for waveform display and alerting and is used by leading pharmaceutical companies through the Discovery platform to collect home-based data for clinical trials. Sibel aims to move healthcare from episodic, reactive monitoring to continuous, predictive clinical intelligence. Recent strategic collaborations with Maruho focus on dermatology-related digital therapeutics, starting with an itch-monitoring application. The company maintains an international presence with an office in Seoul and touts a mission of delivering “Better Health Data for All®.” Financially, Sibel has brought its total Series C funding to $39 million, supported by a mix of healthcare, strategic, and technology investors. Two new board appointments—Kimberly Querrey as Chairwoman and Tim Sullivan as an independent director—add governance and healthcare commercialization expertise to guide upcoming growth.

Led · Series A · Jun 2022

Upstream Bio is advancing UPB-101, a fully human IgG1 monoclonal antibody that binds the TSLP receptor to inhibit signaling in allergic and inflammatory diseases. UPB-101 has completed a first-in-human Phase 1 single-dose escalation in healthy volunteers that was considered safe and well-tolerated, and a Phase 1b multiple ascending dose study in people with asthma is underway. Preclinical data showed inhibition of cytokine production from CD4+ T cells and ILC2 and complete suppression of skin allergic reactions in a monkey model. The company’s IND has been cleared by the FDA to pursue Phase 2 programs in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and Upstream plans registrational Phase 2 trials in both indications. In parallel with Phase 2, Upstream will conduct translational, manufacturing and device development activities to enable a swift transition to Phase 3. The company also reported data supporting a differentiated dosing regimen of at least every 12 weeks; the new capital is intended to fund the next stage of clinical development and support regulatory, market access and commercialization preparation. Upstream Bio launched with a $200 million Series A to advance its lead program UPB-101, a clinical-stage monoclonal antibody that inhibits the TSLP receptor. UPB-101 was acquired from Astellas after completion of initial clinical and preclinical studies, and the company has selected asthma as the first indication for development. Upstream plans to pursue additional TSLP-mediated inflammatory diseases and to build a pipeline of assets addressing immune-mediated diseases. The company emphasizes that inhibiting TSLP signaling is a validated mechanism positioned upstream of targets such as IL-4, IL-5, IL-13, IL-17 and IgE, which could allow a single treatment to impact multiple pathological processes. The Series A was led jointly by OrbiMed and Maruho Co., Ltd., with participation from Access Biotechnology, Decheng Capital, HBM Healthcare Investments, TCG X, Omega Funds, Samsara BioCapital and Altshuler Shaham Provident Funds Ltd., providing capital to advance clinical development. Upstream is led by an experienced executive team including CEO Samantha Truex and CMO Aaron Deykin, who will lead translational and development efforts.

Participated · Series B · Jun 2013

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients. The company’s portfolio includes five product candidates targeting significant market opportunities, including three late-stage programs: Cimzia (certolizumab pegol) in development with UCB Pharma for moderate-to-severe plaque psoriasis, DRM04 for hyperhidrosis, and DRM01, a topical sebum inhibitor for acne. Dermira is headquartered in Redwood City, California. The company completed a $51 million Series C financing to support its programs. Dermira also announced key executive appointments (Andrew Guggenhime as COO and CFO; Christine Conroy as SVP, Regulatory Affairs; Christine Ring as VP, Legal) and expanded its board with four new directors, reflecting efforts to strengthen commercial, regulatory and corporate functions. For more information, the company directs readers to its website, www.dermira.com. Dermira is a development-stage biotech focused on developing and commercializing innovative therapies in dermatology. The company is advancing a portfolio that includes lemuteporfin, a topical photodynamic therapy for acne, and several novel topical small-molecule therapeutics targeting acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Dermira was founded and seed financed in late 2010 by former members of the Peplin and Connetics leadership teams, including Tom Wiggans and Dr. Eugene Bauer, and is led by CEO Tom Wiggans. The company is headquartered in Redwood City, California. Dermira says the new funding provides resources to continue advancing its robust pipeline of novel therapeutics for serious dermatological conditions. Maruho’s participation brings global dermatology expertise and a potential industry partner for development and commercialization. Dermira is a development-stage, private company focused on developing and commercializing new therapies for dermatologic conditions. The company’s portfolio includes lemuteporfin, a topical photodynamic therapy for acne licensed from QLT Inc., and a pipeline of novel topical small-molecule therapeutics targeting sebaceous gland hyperactivity and inflammatory skin diseases. Dermira was founded and seed financed in late 2010 by former members of the Peplin and Connetics leadership teams and is headquartered in Redwood City, California. In conjunction with its Series A closing the company acquired Valocor Therapeutics, adding development-stage dermatology programs for acne and inflammatory skin diseases. Leadership includes CEO Tom Wiggans and CMO Dr. Eugene Bauer. Dermira plans to use the Series A proceeds to advance and commercialize its product pipeline and to pursue additional licensing or acquisition opportunities in dermatology.